Cargando…

Adjuvant Use of Ivabradine in Acute Heart Failure due to Myocarditis

We report two cases of young men in whom acute heart failure due to myocarditis was diagnosed. The patients had been transferred to the intensive care unit (ICU) with commencing symptoms of acute heart failure and consecutive multiorgan failure for further treatment and to evaluate the indication fo...

Descripción completa

Detalles Bibliográficos
Autores principales:	Franke, Jennifer, Schmahl, Dorothee, Lehrke, Stephanie, Pribe, Regina, Bekeredjian, Raffi, Doesch, Andreas O., Ehlermann, Philipp, Schnabel, Philipp, Katus, Hugo A., Zugck, Christian
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Hindawi Publishing Corporation 2011
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3180827/ https://www.ncbi.nlm.nih.gov/pubmed/21966292 http://dx.doi.org/10.1155/2011/203690

Ejemplares similares

Adverse events in families with hypertrophic or dilated cardiomyopathy and mutations in the MYBPC3 gene
por: Ehlermann, Philipp, et al.
Publicado: (2008)

Five-year results of heart rate control with ivabradine or metoprolol succinate in patients after heart transplantation
por: Rivinius, Rasmus, et al.
Publicado: (2020)

Correction to: Five-year results of heart rate control with ivabradine or metoprolol succinate in patients after heart transplantation
por: Rivinius, Rasmus, et al.
Publicado: (2021)

Heart rate reduction for 36 months with ivabradine reduces left ventricular mass in cardiac allograft recipients: a long-term follow-up study
por: Doesch, Andreas O, et al.
Publicado: (2013)

Etiology-specific assessment of predictors of long-term survival in chronic systolic heart failure
por: Franke, Jennifer, et al.
Publicado: (2015)

Transfemoral aortic valve replacement for severe aortic valve regurgitation in a patient with a pulsatile‐flow biventricular assist device
por: Gomes, Bruna, et al.
Publicado: (2018)

Effects of oral valganciclovir prophylaxis for cytomegalovirus infection in heart transplant patients
por: Doesch, Andreas O, et al.
Publicado: (2012)

Ivabradine Treatment in a Chronic Heart Failure Patient Cohort: Symptom Reduction and Improvement in Quality of Life in Clinical Practice
por: Zugck, Christian, et al.
Publicado: (2014)

Increased adherence eight months after switch from twice daily calcineurin inhibitor based treatment to once daily modified released tacrolimus in heart transplantation
por: Doesch, Andreas O, et al.
Publicado: (2013)

Conversion to generic cyclosporine A in stable chronic patients after heart transplantation
por: Kraeuter, Maximilian, et al.
Publicado: (2013)

COPD in patients after heart transplantation is associated with a prolonged hospital stay, early posttransplant atrial fibrillation, and impaired posttransplant survival
por: Rivinius, Rasmus, et al.
Publicado: (2018)

Elevated pre‐transplant pulmonary vascular resistance is associated with early post‐transplant atrial fibrillation and mortality
por: Rivinius, Rasmus, et al.
Publicado: (2020)

Ivabradine tolerability in heart failure
por: Birkhoelzer, Sarah, et al.
Publicado: (2018)

Chronic digitalis therapy in patients before heart transplantation is an independent risk factor for increased posttransplant mortality
por: Rivinius, Rasmus, et al.
Publicado: (2017)

Combined amiodarone and digitalis therapy before heart transplantation is associated with increased post‐transplant mortality
por: Rivinius, Rasmus, et al.
Publicado: (2020)

The Protective Effects of Ivabradine in Preventing Progression from Viral Myocarditis to Dilated Cardiomyopathy
por: Yue-Chun, Li, et al.
Publicado: (2016)

CMR findings in patients referred for suspected myocarditis following mRNA-based COVID vaccination compared with pre-COVID myocarditis referrals: A single-centre observational study
por: Seitz, Andreas, et al.
Publicado: (2022)

Superior rejection profile during the first 24 months after heart transplantation under tacrolimus as baseline immunosuppressive regimen
por: Helmschrott, Matthias, et al.
Publicado: (2014)

Advantageous effects of immunosuppression with tacrolimus in comparison with cyclosporine A regarding renal function in patients after heart transplantation
por: Helmschrott, Matthias, et al.
Publicado: (2015)

Impact of ivabradine in decompensated heart failure due to cancer therapy‐related cardiac dysfunction
por: Nakano, Yusuke, et al.
Publicado: (2021)

Prognostic value of myocardial strain analysis with cardiac magnetic resonance in patients with dilated cardiomyopathy
por: Buss, Sebastian, et al.
Publicado: (2014)

Ivabradine Treatment Reduces Cardiomyocyte Apoptosis in a Murine Model of Chronic Viral Myocarditis
por: Li-Sha, Ge, et al.
Publicado: (2018)

Effects of vildagliptin (Galvus®) therapy in patients with type 2 diabetes mellitus after heart transplantation
por: Gueler, Ibrahim, et al.
Publicado: (2013)

Green tea halts progression of cardiac transthyretin amyloidosis: an observational report
por: Kristen, Arnt V., et al.
Publicado: (2012)

Advances in the management of heart failure: the role of ivabradine
por: Müller-Werdan, Ursula, et al.
Publicado: (2016)

Ivabradine as an Adjuvant Agent for Severe Heart Failure Occurring in the Early Phase after Allogeneic Hematopoietic Cell Transplantation
por: Yanagiya, Ryo, et al.
Publicado: (2022)

Corrigendum: Ivabradine Treatment Reduces Cardiomyocyte Apoptosis in a Murine Model of Chronic Viral Myocarditis
por: Li-Sha, Ge, et al.
Publicado: (2019)

Haemodynamic effects of percutaneous mitral valve edge‐to‐edge repair in patients with end‐stage heart failure awaiting heart transplantation
por: Geis, Nicolas A., et al.
Publicado: (2018)

Impact of Ivabradine on Inflammatory Markers in Chronic Heart Failure
por: Rohm, Ilonka, et al.
Publicado: (2016)

Cost‐Effectiveness of Ivabradine for Heart Failure in the United States
por: Kansal, Anuraag R., et al.
Publicado: (2016)

Ivabradine in Congestive Heart Failure: Patient Selection and Perspectives
por: Sattar, Yasar, et al.
Publicado: (2019)

Comparison of Effects of Ivabradine versus Carvedilol in Murine Model with the Coxsackievirus B3-Induced Viral Myocarditis
por: Yue-Chun, Li, et al.
Publicado: (2012)

Ivabradine in sepsis
por: Nair, Abhijit S, et al.
Publicado: (2013)

Procedural advantages of a novel coronary stent design with ultra-thin struts and bioabsorbable abluminal polymer coating in an all-comers registry
por: Abu Sharar, Haitham, et al.
Publicado: (2018)

Economic evaluation of ivabradine in the treatment of chronic heart failure in Greece
por: Kourlaba, Georgia, et al.
Publicado: (2014)

Risk-benefit assessment of ivabradine in the treatment of chronic heart failure
por: Urbanek, Irmina, et al.
Publicado: (2014)

Role of Ivabradine in Patients with Heart Failure with Preserved Ejection Fraction
por: Nadeem, Muhammad, et al.
Publicado: (2020)

Association of ivabradin use with ventricular arrhythmias in heart failure patients
por: Pay, L, et al.
Publicado: (2023)

Ivabradine in patients with heart failure: a systematic literature review
por: Khan, Zeba M., et al.
Publicado: (2023)

Analysis of malignancies in patients after heart transplantation with subsequent immunosuppressive therapy
por: Rivinius, Rasmus, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_6vv5prrut760m5a5omakinor5j